World Health Organization Sounds Warning Over Severe Lack of Obesity Injections
Under a tenth of individuals who could benefit from GLP-1 drugs like Wegovy have access to them, caution the WHO as it issues its inaugural guidance on the drugs.
With over a billion people worldwide currently obese, it is advocating for more widespread and fairer access to these injectable treatments.
Per estimates, in excess of 2,000,000,000 could be living with obesity by 2030 if no action is taken.
"Our latest guidelines affirms that excess weight is a long-term condition that can be addressed with thorough and ongoing treatment," remarked the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, constrained manufacturing, and supply-chain constraints are significant hurdles to broad access to the jabs that can aid individuals in losing significant body mass, explains the organization.
Skinny Jab Shortage
Even in the current most optimistic outlook, the supply of such drugs could only cover about 100 million people – fewer than 10% of those who need them, according to the health organization.
The recommendation calls on governments and firms to widen availability, by measures like patent sharing.
A patent on a key compound – the primary component of a leading brand – is set to lapse in several countries in 2026.
The Way Obesity Jabs Operate
The injections imitate a body's own hormone to reduce digestion speed, suppress the appetite and increase feelings of fullness so people reduce food intake.
People commonly see weight reduction after several weeks of commencing the weekly injections.
Evidence indicates users may regain a significant portion after a year of stopping the medication, when their usual food cravings resume.
To be overweight or obese increases your risk for experiencing diseases, such as diabetes, heart disease, brain attack, and certain malignancies.
Obesity affects people in countries worldwide and was responsible for over three and a half million fatalities worldwide in 2024, per the WHO.
